ĐÁNH GIÁ GIAI ĐOẠN ĐẦU HIỆU QUẢ ĐIỀU TRỊ TIÊM BEVACIZUMAB DƯỚI KẾT MẠC TRÊN BỆNH NHÂN CÓ TÂN MẠCH GIÁC MẠC

Abstract

Purpose: This study aims to evaluate the effectiveness of reducing corneal neovascularization by subconjunctival bevacizumab injection before keratoplasty. Methods: A prospective case series included 10 eyes of 10 patients with corneal neovascularization that are indications for keratoplasty. Each eye received 3 doses of bevacizumab 2.5 mg/0.1 mL at 1-month intervals. Clinical examinations were performed during 3 months after treatment. Results: Corneal neovascularization gradually decreased over time of follow-up and decreased significantly after 3 months. The corneal neovascularization area was 6,49 ± 4,16%% at baseline, 4,71 ± 3,82%  at 3 months (reduced 28,29 ± 14,91%, p=0,01); the neovascular invasion area was 61,84 ± 22,08% at baseline, 59,31 ± 23,20% at 3 months (reduced 4,58 ± 7,78%, p=0,06); the average vessels diameter was 0.062 ± 0.014mm at baseline, 0.056 ± 0.017 mm at 3 months (reduced 11,18 ± 12,62%, p=0,01), and the extent decreased from 7,30 ± 3,43 to 6,90 ± 3,70 clock hours (reduced 6,79 ± 14,91%, p=0,005). The only local complication observed was subconjunctival hemorrhage at the injection site accounting for 10%. In addition, no systemic complications were recorded. Conclusion: Short-term results show that subconjunctival bevacizumab can be safely and effectively used to treat corneal neovascularization before keratoplasty, suggesting a strategy to improve keratoplasty prognosis.